Thrombocytopenia and platelet hypoaggregation induced by Bothrops asper snake venom

Summary

Thrombocytopenia and platelet dysfunction occur in patients bitten by Bothrops sp snakes in Latin America. An experimental model was developed in mice to study the effects of B. asper venom in platelet numbers and function. Intravenous administration of this venom induces rapid and prominent thrombocytopenia and ex vivo platelet hypoaggregation. The drop in platelet numbers was primarily due to aspercetin, a protein of the C-type lectin family which induces von Willebrand factor-mediated platelet aggregation/agglutination. In addition, the effect of class P-III hemorrhagic metalloproteinases on the microvessel wall also contributes to thrombocytopenia since jararhagin, a P-III metalloproteinase, reduced platelet counts. Hypoaggregation was associated with the action of procoagulant and defibrin(ogen)ating proteinases jararacussin-I (a thrombin-like serine proteinase) and basparin A (a prothrombin activating metalloproteinase). At the doses which induced hypoaggregation, these enzymes caused defibrin(ogen)ation, increments in fibrin(ogen) degradation products and D-dimer and prolongation of the bleeding time. Incubation of B. asper venom with batimastat and α₂-macroglobulin abrogated the hypoaggregating activity, confirming the role of venom proteinases in this effect. Neither aspercetin nor the defibrin(ogen)ating and hypoaggregating components induced hemorrhage upon intravenous injection. However, aspercetin, but not the thrombin-like or the prothrombin-activating proteinases, potentiated the hemorrhagic activity of two hemorrhagic metalloproteinases in the lungs.

Keywords

Snake venom - coagulopathy - defibrin(ogen)ation - thrombocytopenia - hypoaggregation

• References

• 1 Warrell DA. Snakebites in Central and South America: epidemiology, clinical features, and clinical management. In: The Venomous Reptiles in the Western Hemisphere. Campbell II JA, Lamar WW. Comstock Ithaca: 2004: 709-61.
• 2 Kamiguti AS, Cardoso JLC, Theakston RDG. et al. Coagulopathy and haemorrhage in human victims of Bothrops jararaca envenoming in Brazil. Toxicon 1991; 29: 961-72.
• 3 Otero R, Tobón GS, Gómez LF. et al. Accidente ofídico en Antioquia y Chocó. Aspectos clínicos y epidemiológicos (marzo de 1989-febrero de 1990). Acta Méd Colomb 1992; 17: 229-49.
• 4 Cardoso JLC, Fan HW, Franca FOS. et al. Randomized comparative trial of three antivenoms in the treatment of envenoming by lance-headed vipers (Bothrops jararaca) in Sao Paulo, Brazil. Q J Med 1993; 86: 315-25.
• 5 Fan HW, Cardoso JL. Clinical toxicology of snake bites in South America. In: Handbook of Clinical Toxicology of Animal Venoms and Poisons. Meier J, White J. CRC Press; Florida: 1995: 667-88.
• 6 Gutiérrez JM. Clinical toxicology of snake bite in Central America. In: Handbook of Clinical Toxicology of Animal Venoms and Poisons. Meier J, White J. CRC Press; Florida: 1995: 645-65.
• 7 Kini RM, Evans HJ. Effects of snake venom proteins on blood platelets. Toxicon 1990; 28: 1387-422.
• 8 Markland FS. Snake venoms and the hemostatic system. Toxicon 1998; 36: 1749-800.
• 9 Aragón-Ortiz F, Gubensek F. Characterization of thrombin-like proteinase from Bothrops asper venom. In: Toxins: Animal, Plant and Microbial. Rosenberg P. Pergamon Press; Oxford: 1978: 107-11.
• 10 Loría GD, Rucavado A, Kamiguti AS. et al. Characterization of ‘basparin A’, a prothrombin-activating metalloproteinase, from the venom of the snake Bothrops asper that inhibits platelet aggregation and induces defibrination and thrombosis. Arch Biochem Biophys 2003; 418: 13-24.
• 11 Rucavado A, Escalante T, Gutiérrez JM. Effect of the metalloproteinase inhibitor batimastat in the systemic toxicity induced by Bothrops asper snake venom: understanding the role of metalloproteinases in envenomation. Toxicon 2004; 43: 417-24.
• 12 Peña-Chavarría A, Villarejos VM, Zomer M. Clinical importance of prothrombin time determination in snake-venom poisoning. Am J Trop Med Hyg 1970; 19: 342-4.
• 13 Barrantes A, Solís V, Bolaños R. Alteración de los mecanismos de la coagulación en el envenenamiento por Bothrops asper (terciopelo). Toxicon 1985; 23: 399-407.
• 14 Sano-Martins IS, Santoro ML, Castro SCB. et al. Platelet aggregation in patients bitten by the Brazilian snake Bothrops jararaca . Thromb Res 1997; 87: 183-95.
• 15 Rucavado A, Soto M, Kamiguti AS. et al. Characterization of aspercetin, a platelet aggregating component from the venom of the snake Bothrops asper which induces thrombocytopenia and potentiates metalloproteinase- induced hemorrhage. Thromb Haemost 2001; 85: 710-5.
• 16 Pinto A, Angulo Y, Jiménez R. et al. Isolation of bothrasperin, a disintegrin with potent platelet aggregation inhibitory activity, from the venom of the snake Bothrops asper . Rev Biol Trop 2003; 51: 253-9.
• 17 Paine MJI, Desmon HP, Theakston RDG. et al. Purification, cloning and molecular characterization of a high molecular weight hemorrhagic metalloproteinase, jararhagin, from Bothrops jararaca venom. J Biol Chem 1992; 267: 22869-76.
• 18 Gutiérrez JM, Romero M, Díaz C. et al. Isolation and characterization of a metalloproteinase with weak hemorrhagic activity from the venom of the snake Bothrops asper (terciopelo). Toxicon 1995; 33: 19-29.
• 19 Watanabe L, Shannon JD, Valente RH. et al. Amino acid sequence and crystal structure of BaP1, a metalloproteinase from Bothrops asper snake venom that exerts multiple tissue-damaging activities. Prot Sci 2003; 12: 2273-81.
• 20 Bortoleto RK, Murakami MT, Watanabe L. et al. Purification, characterization and crystallization of Jararacussin- I, a fibrinogen-clotting enzyme isolated from the venom of Bothrops jararacussu . Toxicon 2002; 40: 1307-12.
• 21 Kaiser II, Gutiérrez JM, Plummer D. et al. The amino acid sequence of a myotoxic phospholipase from the venom of Bothrops asper . Arch Biochem Biophys 1990; 278: 319-25.
• 22 Franceschi A, Rucavado A, Mora N. et al. Purification and characterization of BaH4, a hemorrhagic metalloproteinase from the venom of the snake Bothrops asper . Toxicon 2000; 38: 63-77.
• 23 Tijssen P. Practice and Theory of Enzyme Immunoassays. Amsterdam: Elsevier; 1985
• 24 Gené JA, Roy A, Rojas G. et al. Comparative study on coagulant, defibrinating, fibrinolytic and fibrinogenolytic activities of Costa Rican crotaline snake venoms and their neutralization by a polyvalent antivenom. Toxicon 1989; 27: 841-8.
• 25 Denis C, Methia N, Frenette PS. et al. A mouse model of severe von Willebrand disease: defects in hemostasis and thrombosis. Proc Natl Acad Sci USA 1998; 95: 9524-9.
• 26 Moura da Silva AM, Línica A, Della-Casa MS. et al. Jararhagin ECD-disintegrin domain: expression in Escherichia coli and inhibition of the platelet-collagen interaction. Arch Biochem Biophys 1999; 369: 295-301.
• 27 Escalante T, Rucavado A, Kamiguti AS. et al. Bothrops asper metalloproteinase BaP1 is inhibited by α2-macroglobulin and mouse serum and does not induce systemic hemorrhage or coagulopathy. Toxicon 2004; 43: 213-7.
• 28 Kamiguti AS, Hay CR, Zuzel M. Inhibition of collagen- induced platelet aggregation as the result of cleavage of α2β1 integrin by the snake venom metalloproteinase jararhagin. Biochem J 1996; 320: 635-41.
• 29 Escalante T, Núñez J, Moura da Silva AM. et al. Pulmonary hemorrhage induced by jararhagin, a metalloproteinase from Bothrops jararaca snake venom. Toxicol Appl Pharmacol 2003; 193: 17-28.
• 30 Brinkhous KM, Barnes D, Potter JY. et al. Von Willebrand syndrome induced by a Bothrops venom factor: Bioassay for venom coagglutinin. Pro Natl Acad Sci USA 1981; 78: 3230-4.
• 31 Sanders WE, Read MS, Reddick RL. et al. Thrombotic thrombocytopenia with von Willebrand factor deficiency induced by botrocetin. An animal model. Lab Invest 1988; 59: 443-52.
• 32 Sen U, Vasudevan S, Subbarao G. et al. Crystal structure of the von Willebrand factor modulator botrocetin. Biochemistry 2001; 40: 345-52.
• 33 Fukuda K, Doggett T, Laurenzi IJ. et al. The snake venom protein botrocetin acts as a biological brace to promote dysfunctional platelet aggregation. Nature Struc Mol Biol 2005; 12: 152-9.
• 34 Slade CL, Andes WA, Mason AD. Platelet aggregation following defibrination with ancrod. Thromb Haemost 1976; 36: 424-9.
• 35 Ownby CL, Bjarnason JB, Tu AT. Hemorrhagic toxins from rattlesnake (Crotalus atrox) venom. Pathogenesis of hemorrhage induced by three purified toxins. Am J Pathol 1978; 93: 201-18.
• 36 Ownby CL, Geren CR. Pathogenesis of hemorrhage induced by hemorrhagic proteinase IV from timber rattlesnake (Crotalus horridus horridus) venom. Toxicon 1987; 25: 517-26
• 37 Moreira L, Borkow G, Ovadia M. et al. Pathological changes induced by BaH1, a hemorrhagic proteinase isolated from Bothrops asper (terciopelo) snake venom, on mouse capillary blood vessels. Toxicon 1994; 32: 977-87.
• 38 Kamiguti AS, Theakston RDG, Desmond H. et al. Systemic haemorrhage in rats induced by a haemorrhagic fraction from Bothrops jararaca venom. Toxicon 1991; 29: 1097-105.
• 39 Konstam MA, Brockway BA, Aronovitz MJ. et al. Kinetics of pulmonary platelet deposition and clearance during thrombin-induced microembolism in rabbits. Exp Lung Res 1989; 15: 867-79.
• 40 Santoro ML, Sano-Martins IS. Platelet dysfunction during Bothrops jararaca snake envenomation in rabbits. Thromb Haemost 2004; 92: 369-83.
• 41 Chang MC, Huang TF. The antiplatelet activity of ancrod on administration to rabbits. J Lab Clin Med 1995; 125: 508-16.
• 42 Santoro ML, Sano-Martins IS, Chamone DAF. In vivo platelet activation induced by Bothrops jararaca venom in rabbits. Platelets 1994; 5: 162-70.
• 43 Thorsen LI, Brosstad F, Gogstad G. et al. Competitions between fibrinogen with its degradation products for interactions with the platelet-fibrinogen receptor. Thromb Res 1986; 44: 611-23.
• 44 Pasqua JJ, Pizzo SV. The role of ligand-ligand interactions in competition by fibrinogen and fibrin degradation products for fibrinogen binding to human platelets. Biochim Biophys Acta 1983; 757: 282-7.
• 45 Chen CS, Chou SH, Thiagarajan P. Fibrin(ogen) peptide Bβ 15–42 inhibits platelet aggregation and fibrinogen binding to activated platelets. Biochemistry 1988; 27: 6121-6.
• 46 Rodrigues VM, Soares AM, Andriao-Escarso SH. et al. Pathological alterations induced by neuwiedase, a metalloproteinase isolated from Bothrops neuwiedi snake venom. Biochimie 2001; 83: 471-9.
• 47 Bjarnason JB, Fox JW. Hemorhagic metalloproteinases from snake venoms. Pharmac Ther 1994; 62: 325-72.
• 48 Baramova EN, Shannon JD, Bjarnason JB. et al. Interaction of hemorrhagic metalloproteinases with human α2-macroglobulin. Biochemistry 1990; 29: 1069-74.
• 49 Kamiguti AS, Desmond HP, Theakston RDG. et al. Ineffectiveness of the inhibition of the main hemorrhagic metalloproteinase from Bothrops jararaca venom by its only plasma inhibitor, α2-macroglobulin. Biochim Biophys Acta 1994; 1200: 307-4.
• 50 Estevao-Costa MI, Diniz CR, Magalhaes A. et al. Action of metalloproteinases mutalysin I and II on several components of the hemostatic and fibrinolytic systems. Thromb Res 2000; 99: 363-76.